Wednesday , May 24 2017
Home / EconLog Library / Dan Klein on Scott Gottlieb

Dan Klein on Scott Gottlieb

Summary:
Dan Klein comments on Donald Trump's FDA nominee for the Heartland Institute. Klein, with Alex Tabarrok, edits the FDA Review project of the Independent Institute. On Gottlieb, Klein is very positive:Scott Gottlieb is not a William Lloyd Garrison, but he motions consistently in the liberalization direction, toward reforms that would move the ball to the 45-yard line. Regarding the permission process, he has favored extending accelerated review to wider categories of drugs, simplifying permitting of generics, and depending more on surrogate-measure evidence, existing data, approval in other nations, and post-market follow-up. For patients, he has favored expanding "the right to try" or compassionate use. He has favored liberalizing manufacturer speech regarding off-label uses. He would, therefore, make the FDA less stingy with the permissions it issues. Also, he has favored making the FDA explain its decision when declining to permit a drug.Read the whole thing.

Topics:
Alberto Mingardi considers the following as important:

This could be interesting, too:

Don Boudreaux writes Some Links

David Henderson writes Thoma on the Financial Choice Act

Don Boudreaux writes Some Links

Don Boudreaux writes Some Links

Dan Klein comments on Donald Trump's FDA nominee for the Heartland Institute. Klein, with Alex Tabarrok, edits the FDA Review project of the Independent Institute.

On Gottlieb, Klein is very positive:

Scott Gottlieb is not a William Lloyd Garrison, but he motions consistently in the liberalization direction, toward reforms that would move the ball to the 45-yard line. Regarding the permission process, he has favored extending accelerated review to wider categories of drugs, simplifying permitting of generics, and depending more on surrogate-measure evidence, existing data, approval in other nations, and post-market follow-up. For patients, he has favored expanding "the right to try" or compassionate use. He has favored liberalizing manufacturer speech regarding off-label uses. He would, therefore, make the FDA less stingy with the permissions it issues. Also, he has favored making the FDA explain its decision when declining to permit a drug.

Read the whole thing.
Alberto Mingardi
Mingardi, one of the rising stars of European libertarianism, is the founder and Director General of the Italian free-market think tank, Instituto Bruno Leoni. His areas of interest include the history of economic thought and antitrust and healthcare systems. He is particularly well known for popularizing the work of past scholars under-appreciated by today’s libertarians. Currently an adjunct scholar at the Cato Institute, Mingardi has also worked with the Heritage Foundation, the Atlas Economic Research Foundation, the Acton Institute, and the Centre for a New Europe.

Leave a Reply

Your email address will not be published. Required fields are marked *